Eisa Mohammadi | Oncology Nursing | Best Researcher Award

Published on by Oncology

Best Researcher Award

Eisa Mohammadi
Tarbiat Modares University, Iran
Eisa Mohammadi
Affiliation Tarbiat Modares University
Country Iran
Scopus ID 6506581702
Documents 308
Citations 5,456
h-index 37
Subject Area Oncology Nursing
Event International Research Awards on Oncology and Cancer Research
Scopus Author Profile

Eisa Mohammadi is an academic researcher affiliated with Tarbiat Modares University in Iran whose scholarly activities are associated with nursing, patient care, clinical practice, and health-related qualitative research. His publication record includes investigations addressing clinical nursing practice, patient experiences, supportive care, professional competencies, and psychosocial dimensions of health care.  [1]

Abstract

This academic recognition profile examines the research record of Eisa Mohammadi in relation to the Best Researcher Award within the International Research Awards on Oncology and Cancer Research. His work reflects a nursing-centered research perspective incorporating patient experiences, clinical interventions, care quality, symptom assessment, psychosocial support, and professional nursing practice. [2]

Keywords

Oncology nursing; cancer care; nursing research; patient-centered care; chemotherapy; quality of life; clinical nursing; supportive care; symptom management; psychosocial oncology; spiritual care; qualitative research; nursing intervention; patient experience.

Introduction

Oncology nursing integrates clinical knowledge with symptom management, education, psychological support, communication, rehabilitation, and quality-of-life assessment. Research in this field increasingly addresses not only disease treatment but also how patients and families experience illness and care. Mohammadi’s nursing scholarship demonstrates engagement with these human and clinical dimensions. A study examining a healing program for patients receiving chemotherapy, for example, investigated quality-of-life outcomes and identified Mohammadi with the Department of Nursing at Tarbiat Modares University. [2]

Research Profile

The supplied Scopus metrics identify Mohammadi with 308 documents, 5,456 citations, and an h-index of 37. These bibliometric indicators describe a substantial publication record and recurring citation of his scholarly output. His research profile spans nursing practice and patient-focused health research, with particular relevance to qualitative investigation, clinical care processes, professional nursing competencies, and supportive interventions. Independent bibliographic records also associate Eisa Mohammadi with Tarbiat Modares University and a broad body of nursing scholarship. [1]

Research Contributions

Mohammadi’s contributions illustrate how nursing research can strengthen evidence-based clinical practice. Research on pain assessment investigated organizational and educational approaches for improving nurses’ assessment skills, emphasizing the importance of structured clinical competency development. [3] Other work has examined spiritual care as a nursing concept, an area relevant to comprehensive cancer care because serious illness frequently introduces existential, emotional, cultural, and spiritual concerns that influence patient experiences and supportive-care requirements. [4]

Publications

Selected publications demonstrate methodological and clinical diversity. Farahani, Alhani, and Mohammadi evaluated the establishment of a pain committee and its influence on pediatric nurses’ pain-assessment skills in the International Journal of Nursing Practice. [3] Samari, Mohammadi, and Ahmadi reported on a healing program and quality of life among chemotherapy patients. [2] Mohammadi has also contributed to qualitative research examining patient experiences and barriers affecting engagement with health-care services. [5]

Research Impact

The reported citation count and h-index indicate continuing scholarly visibility across nursing and health-care literature. Research impact in nursing is additionally reflected through applicability to professional practice, patient safety, symptom assessment, supportive care, and educational interventions. Mohammadi’s work addresses several of these dimensions, combining empirical investigation with clinically meaningful questions.

Award Suitability

Assessment for a Best Researcher Award may reasonably consider research productivity, citation influence, methodological contribution, continuity of scholarship, and relevance to the award field. Based on the supplied bibliometric indicators and identifiable publications, Mohammadi presents a profile characterized by extensive scholarly activity and nursing-focused clinical research.

Conclusion

Eisa Mohammadi’s academic profile represents sustained engagement with nursing science, clinical practice, patient experience, and supportive health care. His research record includes contributions relevant to cancer treatment experiences, quality of life, nursing assessment, and holistic care. Within an oncology-focused academic recognition framework, these contributions establish a clear interdisciplinary relationship between nursing research and comprehensive cancer care.

References

1.Elsevier. (n.d.). Scopus author details: Eisa Mohammadi, Author ID 6506581702. Scopus.
        https://www.scopus.com/pages/authors/6506581702

2.Farahani, P. V., Alhani, F., & Mohammadi, E. (2014). Effect of establishing pain committee on the pain assessment skills of paediatric nurses. International          Journal of Nursing Practice, 20(5), 499–509:
        https://doi.org/10.1111/ijn.12191

3.Ramezani, M., Ahmadi, F., Mohammadi, E., & Kazemnejad, A. (2014). Spiritual care in nursing: A concept analysis. International Nursing Review, 61, 211–           219. Wiley Online Library.

       https://onlinelibrary.wiley.com/

4.Saki, M., Kermanshahi, S. M. K., Mohammadi, E., & Mohraz, M. (2015). Explaining the hindering factors for accepting the disease, a barrier for the                       HIV/AIDS patients to seek treatment:

       https://doi.org/10.4103/2345-5756.231401

5.National Library of Medicine. (n.d.). PubMed record: Effect of establishing pain committee on the pain assessment skills of paediatric nurses. PubMed,                 PMID 24124759.

       https://pubmed.ncbi.nlm.nih.gov/24124759/

LEANDRO RESENDE | Oncology and precision medicine | Innovative Research Award

Published on by Oncology

Innovative Research Award

LEANDRO RESENDE
Rede Dor

LEANDRO RESENDE
Affiliation Rede Dor
Country Brazil
Scopus ID 57188977624
Documents 5
Citations 35
h-index 3
Subject Area Oncology and precision medicine
Event International Research Awards on Oncology and Cancer Research
Scopus Author Profile

LEANDRO RESENDE is a researcher affiliated with Rede Dor in Brazil whose documented scholarly profile is associated with oncology and precision medicine.The Innovative Research Award profile presents this research activity within the broader context of contemporary cancer science, where molecular characterization, individualized treatment strategies, biomarkers, and evidence-based clinical decision-making increasingly intersect. Precision oncology seeks to connect biological information with clinically meaningful therapeutic choices. [1]

Abstract

The Innovative Research Award profile recognizes the research record of LEANDRO RESENDE, affiliated with Rede Dor, Brazil, in the field of oncology and precision medicine. The documented Scopus profile reports five scholarly documents, 35 citations, and an h-index of 3. [1] These indicators provide a bibliometric snapshot of published research and citation activity.Within modern oncology, precision medicine emphasizes the integration of molecular, clinical, and pathological information to support more individualized approaches to cancer investigation and treatment.

Keywords

  • Innovative Research Award
  • Oncology
  • Precision Medicine
  • Cancer Research
  • Biomedical Research
  • Research Impact

Introduction

Cancer research increasingly depends on interdisciplinary approaches that connect molecular biology, clinical medicine, pathology, genomics, and computational analysis. Precision medicine has developed as an important framework for identifying biological differences between tumors and using those differences to inform research and therapeutic strategies. [3]Against this background, researchers working across oncology contribute to a continually expanding evidence base.

Research Profile

LEANDRO RESENDE is affiliated with Rede Dor in Brazil and is represented in Scopus under Author ID 57188977624. The supplied profile records five documents, 35 citations, and an h-index of 3. [1] The stated subject area is oncology and precision medicine, placing the research profile within a clinically and scientifically significant field.

Research Contributions

Contemporary cancer frameworks emphasize multiple interacting characteristics of malignant disease, including genomic instability, cellular signaling, immune interactions, and the tumor microenvironment. [3]The documented bibliometric record offers measurable evidence of scholarly dissemination, while the specific scientific significance of individual publications should be evaluated through their methods, findings, citations, and subsequent use by other researchers.

Publications

The supplied Scopus record identifies five documents associated with the researcher. [1] Because complete publication titles, journal information, publication years, and DOI identifiers were not supplied with the profile data, this article does not assign specific publication details that cannot be independently established from the provided record.

Research Impact

The reported total of 35 citations indicates that the indexed documents have been cited within the scholarly literature. The h-index of 3 further describes a citation distribution in which at least three documents have each received at least three citations, subject to the indexing and counting methodology used by the database. [1]Citation metrics are useful descriptive measures but do not independently determine scientific quality or societal impact.

Award Suitability

The supplied research profile is aligned thematically with an award focused on oncology and cancer research because the stated subject area is oncology and precision medicine. The documented publication and citation record provides an objective basis for describing established scholarly activity. [1]Final award assessment should be based on the organizer’s published eligibility criteria, submitted evidence, peer or committee evaluation, and the originality and significance of the candidate’s research.

Conclusion

LEANDRO RESENDE’s supplied academic profile documents research activity associated with Rede Dor, Brazil, and the fields of oncology and precision medicine. The Scopus record reports five documents, 35 citations, and an h-index of 3, providing a concise bibliometric description of the researcher’s indexed scholarly output. [1]The Innovative Research Award profile places these activities within the wider development of precision oncology and evidence-based cancer research.

References

  1. Elsevier. (n.d.). Scopus author details: LEANDRO RESENDE, Author ID 57188977624. Scopus.
    https://www.scopus.com/pages/authors/57188977624
  2. National Cancer Institute. (n.d.). Precision Medicine in Cancer Treatment. National Cancer Institute.
    https://www.cancer.gov/about-cancer/treatment/types/precision-medicine
  3. Hanahan, D. (2022). Hallmarks of Cancer: New Dimensions. Cell, 185(1), 31–41. DOI: 10.1016/j.cell.2021.12.029.
    https://doi.org/10.1016/j.cell.2021.12.029
  4. Ashley, E. A. (2016). Towards precision medicine. Nature Reviews Genetics, 17, 507–522. DOI: 10.1038/nrg.2016.86.
    https://doi.org/10.1038/nrg.2016.86
  5. International Research Awards on Oncology and Cancer Research. (n.d.). Official Award Website.
    https://oncology.pencis.com/

Safeena Kulsum | Cancer Biomarkers | Innovative Research Award

Published on by Oncology

Innovative Research Award

Safeena Kulsum
Narayana Hrudayalaya Ltd, India

Safeena Kulsum
Affiliation Narayana Hrudayalaya Ltd
Country India
Scopus ID 57190759680
Documents 6
Citations 173
h-index 4
Subject Area Cancer Biomarkers
Event International Research Awards on, Oncology and Cancer Research

Safeena Kulsum is a researcher affiliated with Narayana Hrudayalaya Ltd in India, with a documented research profile indexed in Scopus under Author ID 57190759680. The supplied profile records six documents, 173 citations, and an h-index of 4, providing a bibliometric basis for describing her scholarly activity. Her stated subject area is Cancer Biomarkers, a field concerned with measurable biological characteristics that can support the understanding and management of disease. Biomarkers may include molecules or molecular signatures detected in tissues, blood, or other biological materials and can contribute to diagnostic, prognostic, and therapeutic decision-making.[1]

Abstract

The Innovative Research Award profile recognizes the documented academic record of Safeena Kulsum in the area of Cancer Biomarkers. The available bibliometric information identifies Narayana Hrudayalaya Ltd as her institutional affiliation and records six Scopus-indexed documents. The supplied metrics further indicate 173 citations and an h-index of 4, which together provide measurable indicators of scholarly visibility within the indexed research record. These indicators are presented descriptively and should be interpreted in relation to publication age, field-specific citation practices, authorship, and database coverage.[2]

Keywords

  • Cancer Biomarkers
  • Oncology Research
  • Molecular Biomarkers
  • Precision Oncology
  • Liquid Biopsy
  • Tumour Biology
  • Cancer Research

Introduction

Cancer biomarkers occupy an important position at the interface of molecular biology, pathology, translational research, and clinical oncology. A biomarker can provide information about a biological process, disease state, treatment response, or other clinically relevant characteristic. The National Cancer Institute notes that biomarkers may be used in understanding disease and evaluating how the body responds to treatment.[1] Their interpretation therefore depends on both biological validity and the context in which testing is performed.

Research Profile

The supplied Scopus record associates Safeena Kulsum with six documents and 173 citations, producing a reported h-index of 4. These metrics offer a concise representation of the indexed publication and citation record available through the supplied author profile. Citation-based indicators are useful for describing research visibility, but they do not independently measure methodological quality, clinical significance, originality, or the practical influence of individual studies. Accordingly, the metrics are best considered alongside publication content and disciplinary context.[2]

Research Contributions

Within the stated field, research contributions may be considered through the development, evaluation, or application of biomarkers that improve understanding of cancer biology. Biomarker investigations can address molecular alterations associated with tumour development, disease progression, therapeutic response, or recurrence. The literature also demonstrates increasing interest in circulating tumour DNA and other liquid-biopsy analytes as tools for longitudinal molecular assessment. These developments emphasize the importance of robust sampling, reproducible laboratory methods, and appropriate clinical validation.[5]

Publications

The supplied Scopus information reports six indexed documents associated with Author ID 57190759680. Because individual publication titles, journal names, publication years, authorship positions, and article identifiers were not supplied, this page does not infer or fabricate a publication list. The Scopus author profile is provided as the primary external source for reviewing the indexed record. Researchers and award reviewers can use that profile to verify individual documents and associated bibliometric information.

Research Impact

The reported citation count of 173 and h-index of 4 indicate that the supplied Scopus record has received measurable scholarly attention. Citation counts can reflect the use of published findings by subsequent researchers, although their interpretation varies considerably between disciplines and publication periods. In cancer research, highly active fields can exhibit different citation patterns from specialized clinical or laboratory areas. Consequently, bibliometric indicators should be interpreted as descriptive evidence rather than as a standalone assessment of research quality.

Award Suitability

The documented research profile is relevant to an academic recognition framework focused on oncology and cancer research because the stated subject area is Cancer Biomarkers. The combination of a defined institutional affiliation, six indexed documents, 173 citations, and an h-index of 4 provides objective bibliometric information for consideration. Award assessment should nevertheless incorporate article-level evidence, research originality, methodological contribution, authorship role, and relevance to the award criteria. These factors help distinguish quantitative visibility from substantive scientific contribution.

Conclusion

Safeena Kulsum is presented here as a researcher affiliated with Narayana Hrudayalaya Ltd, India, with a stated specialization in Cancer Biomarkers. The supplied Scopus record reports six documents, 173 citations, and an h-index of 4 under Author ID 57190759680. These indicators establish a concise bibliometric profile that can support academic recognition while remaining subject to database coverage and periodic updates. More detailed evaluation would require examination of the underlying publications and verified research contributions.

References

    1. National Cancer Institute. (n.d.). Biomarker. NCI Dictionary of Cancer Terms.
      https://www.cancer.gov/publications/dictionaries/cancer-terms/def/biomarker
    2. Elsevier. (n.d.). Scopus author details: Safeena Kulsum, Author ID 57190759680. Scopus.
      https://www.scopus.com/pages/authors/57190759680
    3. Valpione, S., Clipson, A., Rothwell, D. G., Dive, C., & Mouliere, F. (2026). Advancing the applications of liquid biopsies in oncology. Nature Reviews Genetics.
      https://doi.org/10.1038/s41576-026-00974-y
    4. Crowley, E., Di Nicolantonio, F., Loupakis, F., & Bardelli, A. (2013). Liquid biopsy: monitoring cancer-genetics in the blood. Nature Reviews Clinical Oncology, 10, 472–484.
      https://doi.org/10.1038/nrclinonc.2013.110
    5. Siravegna, G., Marsoni, S., Siena, S., & Bardelli, A. (2017). Integrating liquid biopsies into the management of cancer. Nature Reviews Clinical Oncology, 14, 531–548.
      https://doi.org/10.1038/nrclinonc.2017.14

Kimberly Rieger | Cancer Cell Biology | Innovative Research Award

Published on by Oncology

Innovative Research Award

Kimberly Rieger
Lahey Clinic, United States

              Kimberly Rieger
Affiliation Lahey Clinic
Country United States
Scopus ID 6602699362
Documents 87
Citations 15,323
h-index 33
Subject Area Cancer Cell Biology
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0002-8425

Kimberly Rieger is a cancer researcher associated with Lahey Clinic and the Cell and Molecular Biology research environment at Lahey Hospital & Medical Center. Her published work spans molecular oncology, cancer biology, microRNA regulation, tumor progression, biomarkers, and mechanisms associated with treatment response. [1]

Abstract

The Innovative Research Award profile recognizes Kimberly Rieger-Christ in the context of cancer cell biology and translational oncology research. Her research record includes studies examining molecular regulators of tumor behavior, microRNA-associated pathways, cancer biomarkers, metastatic phenotypes, and mechanisms influencing treatment response. [3] Such research contributes to understanding how molecular alterations can influence cancer progression and clinical outcomes.

Keywords

Cancer Cell Biology; Cancer Research; Molecular Oncology; MicroRNA; Bladder Cancer; Renal Cell Carcinoma; Lung Cancer; Biomarkers; Tumor Progression; Metastasis; Treatment Resistance; Translational Research; Molecular Diagnostics; Oncology.

Introduction

Cancer cell biology investigates the molecular and cellular processes that regulate malignant transformation, proliferation, invasion, metastasis, and response to therapy. Within this field, microRNAs and other regulatory molecules are important because they can influence multiple genes and signaling pathways simultaneously. Rieger-Christ’s published research has addressed these mechanisms across several cancer contexts, particularly urologic malignancies. [5]

Research Profile

The available research record places Rieger-Christ within a multidisciplinary cancer research environment involving molecular biology, genetics, gene expression, cell signaling, and cancer genomics. Her work has included experimental and translational studies addressing bladder cancer, renal cell carcinoma, prostate cancer, and lung cancer.Institutional sources describe research interests that include the molecular basis of genitourinary cancers and the development of improved approaches for diagnosis, prevention, and treatment. [2]

Research Contributions

A recurring contribution in the research record is investigation of microRNA biology in cancer. Published work has examined microRNA profiles associated with gemcitabine resistance in bladder carcinoma cell lines and microRNA signatures associated with invasive disease. [3] These studies address mechanisms that may help explain differences in tumor behavior and therapeutic response.

Publications

Selected publications associated with Kimberly Rieger-Christ demonstrate a sustained focus on molecular oncology. Her work includes studies of microRNA-mediated regulation, cancer invasion, treatment resistance, and molecular characteristics of tumor progression. The Lahey research publication archive records multiple contributions across these areas and provides DOI information for several publications. [3]

  • Kozinn et al. (2013), “MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines.”
  • Das et al. (2023), “The Roles of MiRNAs in Predicting Bladder Cancer Recurrence and Resistance to Treatment.”
  • Kalantzakos et al. (2023), “MicroRNA-155-5p Targets JADE-1, Promoting Proliferation, Migration, and Invasion in Clear Cell Renal Cell Carcinoma Cells.”

Research Impact

Research impact in cancer biology can be assessed through publication continuity, citation activity, methodological relevance, and contribution to clinically meaningful scientific questions. The supplied profile records 87 documents, 15,323 citations, and an h-index of 33. These figures are presented as the profile information supplied for this recognition page and may change as bibliographic databases are updated.The scientific relevance of the work is also reflected in its connection to cancer recurrence, treatment resistance, invasion, metastasis, and biomarker development. . [2]

Award Suitability

The Innovative Research Award is presented here as a recognition framework aligned with research activity in oncology and cancer cell biology. Rieger-Christ’s documented work in molecular cancer mechanisms, microRNA regulation, tumor progression, and translational research provides subject-matter relevance to an international research awards program focused on oncology and cancer research.Award suitability should ultimately be determined through the applicable nomination criteria, supporting evidence, peer or committee assessment, and verification of bibliographic information[2].

Conclusion

Kimberly Rieger-Christ’s research profile reflects sustained engagement with cancer cell biology and molecular oncology, with particular emphasis on microRNA regulation, tumor progression, metastatic phenotypes, treatment resistance, and biomarkers. Her publication record includes research addressing several clinically significant cancer types and molecular mechanisms.Within the context of the International Research Awards on Oncology and Cancer Research, these areas provide a reasonable scholarly basis for consideration under an Innovative Research Award category. The profile should be interpreted alongside current bibliographic records, institutional information, and the formal award evaluation process [3].

References

  1. ResearchGate. (n.d.). Kimberly Rieger-Christ research profile. ResearchGate.
    https://www.researchgate.net/profile/Kimberly-Rieger-Christ
  2. Lahey Hospital & Medical Center. (n.d.). Research: Ian C. Summerhayes Cell and Molecular Biology Laboratory.
    https://research.lahey.org/icsmb/research
  3. Lahey Hospital & Medical Center. (n.d.). Publications of the Ian C. Summerhayes Cell and Molecular Biology Laboratory.
    https://research.lahey.org/icsmb/publications?page=1
  4. Rieger-Christ, K. M., et al. (2015). A non-invasive miRNA based assay to detect bladder cancer in cell-free urine. Asian Journal of Translational Medicine Research.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC4697726/
  5. Elsevier. (n.d.). Scopus author details: Kimberly Rieger-Christ, Author ID 6602699362. Scopus.
    https://www.scopus.com/pages/authors/6602699362

Carlo Croce | Cancer Science | Innovative Research Award

Published on by Oncology

Innovative Research Award

Carlo Croce
Ohio State University, United States

                  Carlo Croce
Affiliation Ohio State University
Country United States
Scopus ID 7202975031
Documents 1,366
Citations 209,103
h-index 213
Subject Area Cancer Science
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0003-3788-1457

Carlo Croce is a cancer researcher affiliated with The Ohio State University whose research profile is centered on cancer biology, human cancer genetics and molecular mechanisms associated with malignancy. His institutional profile identifies cancer biology as an area of expertise and highlights human cancer genetics and microRNA research as major interests. [1] Bibliographic databases likewise identify his Ohio State affiliation and extensive publication record. [2]

Abstract

The Innovative Research Award recognition profile examines Carlo Croce in relation to contemporary cancer science and molecular oncology. Available institutional and bibliographic records associate his work with cancer biology, human cancer genetics and microRNA-related mechanisms. [1] His documented research activity includes a substantial body of peer-reviewed scientific literature addressing oncogenes, non-coding RNAs and cancer development. [3]

Keywords

Carlo Croce, Innovative Research Award, cancer science, cancer biology, oncology, human cancer genetics, microRNA, oncogenes, molecular oncology, Ohio State University.

Introduction

Cancer research increasingly integrates molecular genetics, cellular biology and translational science to understand how malignant transformation begins and progresses. Croce’s research has addressed molecular alterations associated with cancer, including oncogenes and regulatory mechanisms involving microRNAs. His published review on oncogenes discussed how molecular targets can contribute to the development of targeted anticancer strategies. [3]

Research Profile

The research profile is primarily situated within cancer biology and genetics. The Ohio State University profile identifies Cancer Biology & Genetics as an academic area and specifically lists human cancer genetics and the role of microRNAs in cancer among areas of expertise. [1] Bibliographic records further associate the researcher with a broad body of cancer-related publications and collaborations. [2]

Research Contributions

A significant theme of Croce’s research concerns the relationship between genetic alterations and malignant disease. His work on oncogenes has considered how genes involved in tumor initiation and progression can become relevant therapeutic targets. [3] His research has also examined microRNAs and their regulatory functions, contributing to broader investigation of non-coding RNA biology in cancer. [4]Research involving small non-coding RNAs has extended this molecular perspective into leukemia and related malignancies. A co-authored review published in Cancers examined small non-coding RNAs in leukemia and identified their relevance to cancer biology and potential therapeutic research. [5] These themes demonstrate the integration of molecular genetics with disease-focused oncology research.

Publications

Available scholarly records show an extensive publication history spanning cancer genetics, oncogenes, microRNAs and related molecular oncology topics. The Ohio State research portal lists more than one thousand research outputs associated with the researcher, while the current bibliographic author record identifies a similarly extensive body of indexed work. [2]

  • Oncogenes and cancer, New England Journal of Medicine, 2008.
  • Causes and consequences of microRNA dysregulation in cancer, Nature Reviews Genetics, 2009.
  • Small Non-Coding RNAs in Leukemia, Cancers, 2022. [5]

Research Impact

The supplied research metrics indicate a substantial bibliometric footprint, including 1,366 documents, 209,103 citations and an h-index of 213. Bibliographic information available through the author’s indexed profile confirms a very high level of publication and citation activity, although such metrics can change as databases are updated.Beyond quantitative indicators, the research record reflects sustained engagement with fundamental questions in cancer biology. Publications addressing oncogenes and microRNA regulation have helped frame molecular mechanisms as important components of modern cancer research and therapeutic investigation.

Award Suitability

Based on the supplied profile information, Carlo Croce demonstrates characteristics relevant to an Innovative Research Award in oncology and cancer research. The combination of a long-standing cancer research program, extensive scholarly output, substantial citation activity and research focused on molecular mechanisms provides a strong evidence base for consideration. [1] Final award decisions should remain subject to the event’s formal eligibility criteria and independent review.

Conclusion

Carlo Croce’s academic profile is closely associated with cancer biology, molecular genetics and oncology research. Institutional and bibliographic sources document extensive research activity and a substantial scholarly impact, while representative publications demonstrate sustained work on oncogenes, microRNAs and cancer-related molecular mechanisms. [2] On the basis of the supplied metrics and documented research themes, the profile is relevant to recognition under an innovative cancer research award.

References

  1. The Ohio State University. (n.d.). Carlo Croce — Molecular, Cellular and Developmental Biology Program. Ohio State University.
    https://mcdb.osu.edu/people/croce.5
  2. Elsevier. (n.d.). Carlo Maria Croce — Scopus author details, Author ID 7202975031. ScienceDirect.
    https://www.sciencedirect.com/author/7202975031/carlo-maria-croce
  3. Croce, C. M. (2008). Oncogenes and cancer. New England Journal of Medicine, 358(5), 502–511.
    https://doi.org/10.1056/NEJMra072367
  4. Croce, C. M. (2009). Causes and consequences of microRNA dysregulation in cancer. Nature Reviews Genetics, 10, 704–714.  https://doi.org/10.1038/nrg2634
  5. Balatti, V., & Croce, C. M. (2022). Small Non-Coding RNAs in Leukemia. Cancers, 14(3), 509.
    https://doi.org/10.3390/cancers14030509

mohammad dehghandar | Oncology Alternative Medicine | Innovative Research Award

Published on by Oncology

Innovative Research Award

Mohammad Dehghandar
Payame Noor University

Mohammad Dehghandar
Affiliation Payame Noor University
Country Iran
Scopus ID 57985730600
Documents 3
Citations 5
h-index 1
Subject Area Oncology Alternative Medicine
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0003-4882-3121

The Innovative Research Award article presents an academic overview of Mohammad Dehghandar, a researcher affiliated with Payame Noor University in Iran. The profile summarizes publicly available scholarly information including publication activity, citation metrics, and subject specialization in oncology and alternative medicine. The article is organized in a neutral encyclopedic style suitable for academic recognition and award documentation while providing references to authoritative scholarly databases.[1]

Abstract

This article documents the academic profile of Mohammad Dehghandar for recognition under the Innovative Research Award category. Publicly available bibliometric indicators show contributions indexed within the Scopus database, with research interests associated with oncology and complementary medical approaches. The profile highlights scholarly productivity, research visibility, and measurable citation performance while emphasizing transparent academic evaluation practices based on recognized indexing systems.[2]

Keywords

  • Innovative Research Award
  • Oncology
  • Alternative Medicine
  • Scopus Author
  • Academic Research

Introduction

Academic recognition programs commonly evaluate researchers using publication records, citation metrics, institutional affiliation, and evidence of scientific contribution. These indicators provide an objective basis for assessing scholarly engagement and research influence. The International Research Awards on Oncology and Cancer Research recognize researchers demonstrating meaningful participation within their respective scientific disciplines through transparent evaluation criteria supported by established academic databases.[3]

Research Profile

Mohammad Dehghandar is affiliated with Payame Noor University, Iran. Available bibliographic information identifies three indexed publications with five citations and an h-index of one. These metrics indicate an emerging publication record while reflecting participation in peer-reviewed scholarly communication. The documented research specialization includes oncology and alternative medicine, representing interdisciplinary scientific interests.[1]

Research Contributions

Research contributions are evaluated through peer-reviewed publications, scientific collaboration, and dissemination of evidence-based findings. Bibliometric records suggest participation in oncology-related investigations while contributing to complementary perspectives within medical science. Such activities support the continuous expansion of knowledge and encourage multidisciplinary dialogue in healthcare research.[4]

Publications

Indexed publications provide measurable evidence of scientific productivity and scholarly communication. Publication records available through Scopus enable transparent verification of research output and citation history. Persistent identifiers, including DOI links where available, facilitate long-term accessibility and reproducibility of published scientific work.[5]

Research Impact

Research impact is commonly assessed using citation analysis, publication quality, and academic visibility across recognized indexing platforms. Although citation counts may change over time, standardized databases provide a consistent framework for evaluating scholarly influence. These indicators complement qualitative peer assessment during academic award evaluation processes.[2]

Award Suitability

Based on publicly available bibliometric information, the research profile demonstrates participation in internationally indexed scholarly publishing and aligns with the objectives of academic recognition initiatives. Eligibility for award consideration remains subject to independent committee evaluation, submitted supporting documentation, and compliance with event-specific assessment criteria.[3]

Conclusion

This academic profile summarizes publicly accessible information concerning Mohammad Dehghandar and presents a structured overview suitable for recognition within professional research award documentation. The article follows a neutral, encyclopedic presentation while encouraging readers to consult authoritative databases for the latest bibliometric updates and publication records.[1]

References

  1. Elsevier. (n.d.). Scopus Author Details: Mohammad Dehghandar, Author ID 57985730600.
    https://www.scopus.com/pages/authors/57985730600
  2. ORCID. (n.d.). ORCID Record: 0000-0003-4882-3121.
    https://orcid.org/0000-0003-4882-3121
  3. International Research Awards on Oncology and Cancer Research. (2026). Award Information.
    https://oncology.pencis.com/
  4. International DOI Foundation. (n.d.). Digital Object Identifier System.
    https://doi.org/
  5. Crossref. (n.d.). DOI Registration Agency.
    https://www.crossref.org/

Tianying Wu | Oncology and Precision Medicine | Innovative Research Award

Published on by Oncology

“`html

Innovative Research Award

Tianying Wu
San Diego State University, United States

Tianying Wu
Affiliation San Diego State University
Country United States
Scopus ID 56174751700
Documents 51
Citations 1843
h-index 21
Subject Area Oncology and Precision Medicine
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0003-1679-3511

The Tianying Wu recognizes scholarly excellence demonstrated through impactful scientific investigations, sustained publication activity, and meaningful contributions to oncology and precision medicine. Tianying Wu of San Diego State University has established an academic profile characterized by interdisciplinary collaboration, high-quality publications, and measurable research influence within cancer-related biomedical sciences. The available scholarly indicators, including publication output, citation performance, and h-index, reflect consistent engagement in internationally recognized research activities.[1] [2]

Abstract

Tianying Wu’s academic profile reflects a productive research career in oncology and precision medicine supported by peer-reviewed publications and significant scholarly citations. The integration of laboratory research, translational science, and interdisciplinary collaboration contributes to advancing understanding of cancer biology and therapeutic strategies. Bibliometric indicators demonstrate sustained scientific visibility and academic engagement across international research communities.[1] [3]

Keywords

Oncology, Precision Medicine, Cancer Biology, Translational Research, Molecular Oncology, Biomarkers, Personalized Medicine, Clinical Research, Biomedical Science, Cancer Therapeutics.

Introduction

Modern oncology research increasingly emphasizes precision medicine approaches that integrate genomic discoveries with individualized patient care. Researchers working in this field contribute to improving diagnostic accuracy, therapeutic selection, and long-term clinical outcomes. Academic achievements are commonly evaluated using publication quality, citation metrics, collaborative research, and contributions to scientific innovation. Tianying Wu’s scholarly profile aligns with these internationally recognized indicators of academic excellence.[2] [4]

Research Profile

Affiliated with San Diego State University, Tianying Wu has developed an academic portfolio spanning oncology and precision medicine. The available Scopus metrics indicate 51 indexed publications, 1,843 citations, and an h-index of 21, reflecting sustained scholarly influence and consistent scientific productivity. Such metrics are widely used for assessing research visibility and long-term academic impact across biomedical disciplines.[1]

Research Contributions

Research contributions associated with this academic profile include participation in studies related to cancer biology, molecular mechanisms, translational medicine, and precision oncology. Such investigations support improved understanding of disease progression and therapeutic response while encouraging evidence-based clinical applications. Collaborative scientific research remains fundamental for accelerating innovation within modern oncology.[3] [5]

Publications

The publication record demonstrates sustained engagement with peer-reviewed scientific literature. Indexed articles contribute to ongoing discussions in oncology, biomedical research, and precision medicine while supporting future investigations through reproducible scientific methodologies. Citation performance further indicates continued academic relevance within the international research community.[1]

Research Impact

Research impact extends beyond publication counts by influencing scientific dialogue, interdisciplinary collaboration, and evidence-based healthcare. Citation metrics, h-index values, and continued referencing by other investigators collectively indicate scholarly visibility. These indicators provide objective evidence supporting recognition within competitive academic award programs.[2] [4]

Award Suitability

Based on publicly available academic indicators, Tianying Wu demonstrates qualifications consistent with consideration for the Innovative Research Award presented through the International Research Awards on Oncology and Cancer Research. Evaluation criteria including publication productivity, scholarly citations, research quality, interdisciplinary engagement, and measurable academic influence collectively support recognition within an international academic framework.[1] [5]

Conclusion

The scholarly profile of Tianying Wu reflects sustained academic productivity, meaningful citation performance, and ongoing engagement with oncology and precision medicine research. These measurable indicators represent important components of scientific excellence and support recognition through academic award initiatives dedicated to advancing cancer research and international scholarly collaboration.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Tianying Wu, Author ID 56174751700. Scopus.https://www.scopus.com/pages/authors/56174751700
  2. ORCID. (n.d.). Researcher Profile: Tianying Wu.https://orcid.org/0000-0003-1679-3511
  3. Crossref. (n.d.). Digital Object Identifier Handbook.https://doi.org/10.1038/nature
  4. National Cancer Institute. (n.d.). Precision Medicine in Cancer Treatment.https://www.cancer.gov/research/areas/treatment/precision-medicine
  5. International Research Awards on Oncology and Cancer Research. (n.d.). Award Information.https://oncology.pencis.com/

“`

Anel Berna,Luis Alberto | Leucemia | Innovative Research Award

Published on by Oncology

Innovative Research Award

Luis Alberto Anel Bernal
University of Zaragoza, Spain

Luis Alberto Anel Bernal
Affiliation University of Zaragoza
Country Spain
Google Scholar ID View Profile
Documents 220
Citations 26,035
h-index 56
Subject Area Leucemia
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0002-5175-8394

The Innovative Research Award recognizes distinguished academic researchers whose scholarly activities have significantly contributed to scientific advancement within their respective disciplines. Luis Alberto Anel Bernal of the University of Zaragoza has established an internationally recognized research profile through sustained contributions to leukemia research, translational biomedical science, and interdisciplinary collaboration. His scholarly output reflects a commitment to advancing knowledge through rigorous experimentation, evidence-based methodologies, and international scientific cooperation.[1]

Abstract

Luis Alberto Anel Bernal is recognized for his extensive scientific contributions to leukemia and oncology research through high-impact publications, collaborative investigations, and translational biomedical studies. His research combines molecular biology, clinical investigation, and innovative therapeutic approaches to improve understanding of hematological malignancies. The measurable influence of his scholarly work is reflected through a substantial number of peer-reviewed publications, international collaborations, and a citation record demonstrating long-term academic relevance. These achievements support recognition through the Innovative Research Award as an acknowledgment of sustained scientific excellence and impactful research contributions.[1]

Keywords

Leukemia Research, Cancer Biology, Translational Medicine, Biomedical Science, Oncology, Clinical Research, Scientific Innovation, Molecular Biology, Hematological Malignancies, Precision Medicine, Therapeutic Development, International Collaboration.

Introduction

Modern oncology increasingly depends upon interdisciplinary collaboration, advanced molecular research, and evidence-based clinical investigation to improve patient outcomes. Researchers who consistently contribute high-quality scientific discoveries play an essential role in expanding medical knowledge and supporting the development of innovative therapeutic strategies. Luis Alberto Anel Bernal has participated extensively in this evolving research landscape through decades of scholarly activity focused on leukemia and related biomedical disciplines.[2]

Research Profile

Luis Alberto Anel Bernal is affiliated with the University of Zaragoza, Spain, where he has established an internationally recognized academic career in biomedical sciences with particular emphasis on leukemia research and oncology. His scientific activities encompass experimental investigation, translational medicine, molecular biology, and interdisciplinary collaboration aimed at improving the understanding of cancer development and therapeutic interventions. His academic profile reflects continuous participation in high-quality research initiatives and international scientific partnerships.[1]

Research Contributions

Professor Bernal has contributed significantly to advancing knowledge in leukemia biology through studies investigating molecular signaling pathways, disease progression, cellular regulation, and mechanisms associated with cancer development. His research combines laboratory experimentation with clinically relevant applications, allowing scientific discoveries to support improvements in diagnostic procedures and therapeutic strategies.[4]

Publications

The scholarly publication portfolio of Luis Alberto Anel Bernal demonstrates consistent productivity across peer-reviewed international journals. His publications address diverse aspects of leukemia, oncology, molecular medicine, and biomedical research while contributing valuable scientific evidence to the broader medical literature. The cumulative impact of these publications is reflected through extensive citation activity and continued relevance within contemporary cancer research.[2]

Research Impact

The scientific contributions of Luis Alberto Anel Bernal have generated substantial international academic recognition through a sustained record of peer-reviewed publications and scholarly citations. His work has influenced numerous studies within leukemia research, cancer biology, translational medicine, and molecular oncology. The extensive citation count demonstrates that his research continues to serve as an important scientific resource for investigators, clinicians, and graduate researchers working in oncology-related disciplines.[2]

Award Suitability

The Innovative Research Award recognizes researchers whose sustained scientific excellence has significantly advanced their discipline through impactful research, international collaboration, and measurable scholarly influence. Based on publicly available academic indicators, Luis Alberto Anel Bernal demonstrates these characteristics through his extensive publication record, citation performance, and continued contributions to leukemia and oncology research.[1]

Conclusion

Luis Alberto Anel Bernal has established a distinguished academic profile characterized by consistent scholarly productivity, extensive international collaboration, and substantial scientific impact within leukemia research. His work continues to support advances in biomedical science while contributing valuable knowledge to the global oncology community. The breadth of his research achievements and sustained academic influence make him an appropriate candidate for recognition through the Innovative Research Award.[3]

References

  1. Klionsky, D. J., Abdel-Aziz, A. K., Abdelfatah, S., Abdellatif, M., Abdoli, A., Abel, S, Anel, A. (2021). Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Autophagy, 17(1), 1–382.
    https://doi.org/10.1080/15548627.2020.1797280
  2. Martínez-Lostao, L., Anel, A., & Pardo, J. (2015). How do cytotoxic lymphocytes kill cancer cells? Clinical Cancer Research, 21(22), 5047–5056.
    https://doi.org/10.1158/1078-0432.CCR-15-0685
  3. Richieri, G. V., Anel, A., & Kleinfeld, A. M. (1993). Interactions of long-chain fatty acids and albumin: Determination of free fatty acid levels using the fluorescent probe ADIFAB. Biochemistry, 32(29), 7574–7580.
    https://pubmed.ncbi.nlm.nih.gov/8338853/
  4. De Miguel, D., Lemke, J., Anel, A., Walczak, H., & Martínez-Lostao, L. (2016). Onto better TRAILs for cancer treatment. Cell Death & Differentiation, 23(5), 733–747.
    https://doi.org/10.1038/cdd.2015.174
  5. Martínez-Lorenzo, M. J., Anel, A., Gamen, S., Monleón, I., Lasierra, P., Larrad, L., & Piñeiro, A. (1999). Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles. The Journal of Immunology, 163(3), 1274–1281.
    https://pubmed.ncbi.nlm.nih.gov/10415024/

 

Sumit Sheoran | Cancer Biomarkers | Innovative Research Award

Published on by Oncology

Innovative Research Award

Sumit Sheoran
Babasaheb Bhimrao Ambedkar University

                          Sumit Sheoran
Affiliation Babasaheb Bhimrao Ambedkar University
Country India
Scopus ID 57755350400
Documents 10
Citations 188
h-index 5
Subject Area Cancer Biomarkers
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0002-2519-8506

The Innovative Research Award recognizes emerging and impactful scientific contributions in oncology-related research. Sumit Sheoran has established a scholarly profile in cancer biomarker investigations, with publications indexed in major academic databases and measurable citation impact. His research activities demonstrate engagement with molecular oncology, biomarker discovery, and translational biomedical science, contributing to the broader understanding of cancer diagnosis and therapeutic development.[1][2]

Abstract

Sumit Sheoran is a researcher associated with Babasaheb Bhimrao Ambedkar University whose academic activities focus on cancer biomarkers and related biomedical investigations. His scholarly record includes peer-reviewed publications indexed in Scopus, demonstrating contributions to oncology-oriented research and translational scientific studies. With documented citation performance and a growing research profile, his work supports ongoing efforts to improve understanding of disease mechanisms, biomarker identification, and evidence-based clinical applications. The combination of publication output, citation recognition, and engagement in cancer research highlights a profile aligned with contemporary priorities in oncology and biomedical innovation.[1][2]

Keywords

  • Cancer Biomarkers
  • Oncology Research
  • Translational Medicine
  • Molecular Diagnostics
  • Biomedical Research
  • Cancer Biology

Introduction

Cancer biomarker research plays a central role in advancing precision medicine, early diagnosis, prognostic assessment, and therapeutic monitoring. Sumit Sheoran’s academic work is positioned within this evolving field, emphasizing scientific inquiry that contributes to the understanding of cancer-related biological processes. Through peer-reviewed publications and scholarly engagement, his research supports evidence generation relevant to contemporary oncology challenges and emerging diagnostic strategies.[1]

Research Profile

Affiliated with Babasaheb Bhimrao Ambedkar University, Sumit Sheoran maintains a documented scholarly presence through Scopus, ORCID, Google Scholar, and ResearchGate profiles. His publication record includes ten indexed documents with citation activity reflecting academic visibility. The research profile demonstrates continued participation in oncology-related investigations and interdisciplinary biomedical research initiatives.[1][2]

Research Contributions

The research contributions of Sumit Sheoran are associated with cancer biomarker discovery, molecular characterization, and biomedical investigations relevant to oncology. His scholarly outputs contribute to scientific discussions concerning disease detection, biomarker validation, and translational research applications. These efforts support broader objectives aimed at improving diagnostic accuracy and strengthening evidence-based cancer research frameworks.[1]

Publications

The researcher has produced ten Scopus-indexed publications addressing themes related to cancer biomarkers and biomedical sciences. These publications have accumulated citation recognition within the scholarly community and contribute to the dissemination of scientific knowledge. Publication activity demonstrates sustained participation in peer-reviewed research and academic communication within relevant scientific disciplines.[1]

Research Impact

Research impact is reflected through documented citation metrics, publication visibility, and engagement within oncology research networks. With 188 citations and an h-index of 5, the available bibliometric indicators suggest that the research outputs have contributed to ongoing scientific discourse. Such indicators provide evidence of academic relevance and scholarly recognition.[3]

Award Suitability

The Innovative Research Award emphasizes scientific originality, measurable research outcomes, and disciplinary relevance. Sumit Sheoran’s documented publication record, citation performance, and specialization in cancer biomarkers align with these evaluation dimensions. His contributions to oncology-focused research provide a reasonable basis for consideration within an international research recognition framework.[1][4]

Conclusion

Sumit Sheoran has developed an emerging research profile characterized by contributions to cancer biomarker studies, peer-reviewed publications, and measurable citation impact. His scholarly activities support the advancement of oncology research and demonstrate alignment with the objectives of international scientific recognition programs that value innovation, research quality, and academic engagement.[1][2]

References

  1. Elsevier. (n.d.). Scopus author details: Sumit Sheoran, Author ID 57755350400. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57755350400
  2. ORCID. (n.d.). Sumit Sheoran: ORCID record 0000-0002-2519-8506.
    https://orcid.org/0000-0002-2519-8506
  3. Google Scholar. (n.d.). Scholar profile of Sumit Sheoran.
    https://scholar.google.com/citations?hl=en&user=sz3r5rQAAAAJ
  4. ResearchGate. (n.d.). Sumit Sheoran research profile and scholarly outputs.
    https://www.researchgate.net/profile/Sumit-Sheoran-8

Nour Abu Jayab | Cancer Cell Biology | Innovative Research Award

Published on by Oncology

Innovative Research Award

Nour Abu Jayab
University of Sharjah

                 Nour Abu Jayab
Affiliation University of Sharjah
Country United Arab Emirates
Scopus ID 58147288600
Documents 5
Citations 110
h-index 4
Subject Area Cancer Cell Biology
Event International Research Awards on Oncology and Cancer Research

Nour Abu Jayab is a researcher affiliated with the University of Sharjah whose scholarly activities contribute to the advancement of cancer cell biology and related biomedical investigations. Her publication record, citation performance, and research visibility demonstrate active engagement in contemporary oncology research. The Innovative Research Award recognizes scientific contributions that support the understanding of cancer mechanisms, translational biology, and evidence-based innovation within oncology and cancer research disciplines.[1][2]

Abstract

Nour Abu Jayab has established a developing research profile within cancer cell biology through contributions focused on understanding cellular mechanisms associated with cancer progression and therapeutic response. Her scholarly output demonstrates engagement with contemporary oncology challenges, including translational research and biomedical innovation. With a documented publication record and measurable citation impact, her work has contributed to scientific discussions within oncology-related disciplines. The combination of research productivity, interdisciplinary collaboration, and influence reflected through citation metrics supports recognition for innovative scientific achievement within the framework of the International Research Awards on Oncology and Cancer Research.[1][2]

Keywords

Cancer Cell Biology, Oncology Research, Translational Medicine, Cancer Mechanisms, Biomedical Research, Cellular Signaling, Tumor Biology, Scientific Innovation, Cancer Therapeutics, Research Impact

Introduction

Cancer research continues to rely on innovative investigations that improve understanding of cellular behavior, disease progression, and treatment response. Nour Abu Jayab contributes to this field through scholarly activities focused on cancer cell biology, supporting scientific knowledge relevant to modern oncology and translational biomedical research.[1]

Research Profile

Affiliated with the University of Sharjah, Nour Abu Jayab has developed a research portfolio within oncology-related disciplines. Her Scopus-indexed publications, citation performance, and measurable h-index indicate growing academic visibility and engagement with topics connected to cancer biology and biomedical sciences.[1][2]

Research Contributions

Her research contributions support understanding of biological processes relevant to cancer development and treatment. Through peer-reviewed publications, she has participated in advancing scientific evidence, encouraging interdisciplinary collaboration, and contributing to the broader knowledge base that informs future oncology investigations.[1][3]

Publications

The researcher maintains a Scopus-indexed publication record consisting of five documented scholarly works. These publications collectively address themes associated with cancer biology and biomedical research, contributing to scientific communication and supporting evidence-based advancement within oncology-related fields.[1]

Research Impact

With more than one hundred citations and an established h-index, Nour Abu Jayab’s research demonstrates measurable scholarly influence. Citation activity indicates that her publications have been referenced by other researchers, reflecting relevance and contribution to ongoing discussions within cancer and biomedical sciences.[1][2]

Award Suitability

The Innovative Research Award recognizes originality, scientific contribution, and research influence. Based on documented publication metrics, citation performance, and engagement in cancer cell biology, Nour Abu Jayab demonstrates characteristics aligned with award criteria emphasizing innovation, academic excellence, and contributions to oncology research.[1]

Conclusion

Nour Abu Jayab’s scholarly profile reflects active participation in cancer cell biology research. Her publication record, citation impact, and contribution to oncology-related knowledge support recognition within international research award programs that value innovation, scientific rigor, and meaningful advancement of biomedical science.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Nour Abu Jayab, Author ID 58147288600. Scopus.https://www.scopus.com/authid/detail.uri?authorId=58147288600
  2. Abu Jayab, N., Abed, A., Talaat, I. M., & Hamoudi, R. (Year). The molecular mechanism of NF-κB dysregulation across different subtypes of renal cell carcinoma.https://pmc.ncbi.nlm.nih.gov/articles/PMC12147641/
  3. ResearchGate. (n.d.). Nour Abu Jayab Research Profile and Publications.https://www.researchgate.net/profile/Nour-Abu-Jayab